Amlodipine/candesartan cilexetil - HanAll BioPharma
Alternative Names: Amlodipine/candesartan; Candesartan cilexetil/amlodipine - HanAll BioPharma; HL-068Latest Information Update: 08 Oct 2021
At a glance
- Originator HanAll Biopharma
- Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 08 Oct 2021 Discontinued - Phase-III for Hypertension in South Korea (PO) (HanAll BioPharma pipeline, October 2021)
- 20 Nov 2018 Phase-III development is ongoing in South Korea (HanAll Biopharma pipeline, November 2018)
- 04 Feb 2017 HanAll BioPharma completes prior to enrollment a phase I bioequivalence trial in Healthy volunteers in an Unknown location (PO) (NCT02988362)